Navamedic Valuation
Is NAVA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NAVA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NAVA (NOK31.6) is trading below our estimate of fair value (NOK165.59)
Significantly Below Fair Value: NAVA is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NAVA?
Other financial metrics that can be useful for relative valuation.
What is NAVA's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | NOK 554.61m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.2x |
Enterprise Value/EBITDA | 10.4x |
PEG Ratio | 0.8x |
Price to Earnings Ratio vs Peers
How does NAVA's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 51.9x | ||
VISTN Vistin Pharma | 18.2x | n/a | NOK 1.2b |
PHO Photocure | 108.9x | 88.7% | NOK 1.4b |
AZT ArcticZymes Technologies | 58.9x | 54.1% | NOK 861.1m |
539730 Fredun Pharmaceuticals | 21.7x | n/a | ₹3.8b |
NAVA Navamedic | 22.7x | 27.0% | NOK 558.1m |
Price-To-Earnings vs Peers: NAVA is good value based on its Price-To-Earnings Ratio (22.7x) compared to the peer average (51.8x).
Price to Earnings Ratio vs Industry
How does NAVA's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: NAVA is good value based on its Price-To-Earnings Ratio (22.7x) compared to the European Pharmaceuticals industry average (22.7x).
Price to Earnings Ratio vs Fair Ratio
What is NAVA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 22.5x |
Fair PE Ratio | 23.9x |
Price-To-Earnings vs Fair Ratio: NAVA is good value based on its Price-To-Earnings Ratio (22.7x) compared to the estimated Fair Price-To-Earnings Ratio (23.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | NOK 31.40 | NOK 45.50 +44.9% | 1.1% | NOK 46.00 | NOK 45.00 | n/a | 2 |
Sep ’25 | NOK 29.10 | NOK 45.50 +56.4% | 1.1% | NOK 46.00 | NOK 45.00 | n/a | 2 |
Aug ’25 | NOK 32.00 | NOK 46.50 +45.3% | 1.1% | NOK 47.00 | NOK 46.00 | n/a | 2 |
Jul ’25 | NOK 33.00 | NOK 46.50 +40.9% | 1.1% | NOK 47.00 | NOK 46.00 | n/a | 2 |
Jun ’25 | NOK 33.90 | NOK 49.00 +44.5% | 6.1% | NOK 52.00 | NOK 46.00 | n/a | 2 |
May ’25 | NOK 32.40 | NOK 49.00 +51.2% | 6.1% | NOK 52.00 | NOK 46.00 | n/a | 2 |
Apr ’25 | NOK 35.60 | NOK 51.00 +43.3% | 2.0% | NOK 52.00 | NOK 50.00 | n/a | 2 |
Mar ’25 | NOK 37.00 | NOK 49.00 +32.4% | 2.0% | NOK 50.00 | NOK 48.00 | n/a | 2 |
Feb ’25 | NOK 38.50 | NOK 49.00 +27.3% | 2.0% | NOK 50.00 | NOK 48.00 | n/a | 2 |
Jan ’25 | NOK 36.70 | NOK 49.00 +33.5% | 2.0% | NOK 50.00 | NOK 48.00 | n/a | 2 |
Dec ’24 | NOK 38.50 | NOK 49.00 +27.3% | 2.0% | NOK 50.00 | NOK 48.00 | n/a | 2 |
Nov ’24 | NOK 38.90 | NOK 47.00 +20.8% | 6.4% | NOK 50.00 | NOK 44.00 | n/a | 2 |
Oct ’24 | NOK 39.30 | NOK 47.00 +19.6% | 6.4% | NOK 50.00 | NOK 44.00 | NOK 30.10 | 2 |
Sep ’24 | NOK 32.00 | NOK 47.00 +46.9% | 6.4% | NOK 50.00 | NOK 44.00 | NOK 29.10 | 2 |
Aug ’24 | NOK 36.80 | NOK 50.50 +37.2% | 5.0% | NOK 53.00 | NOK 48.00 | NOK 32.00 | 2 |
Jul ’24 | NOK 38.50 | NOK 49.00 +27.3% | 8.2% | NOK 53.00 | NOK 45.00 | NOK 33.00 | 2 |
Jun ’24 | NOK 37.90 | NOK 49.00 +29.3% | 8.2% | NOK 53.00 | NOK 45.00 | NOK 33.90 | 2 |
May ’24 | NOK 36.40 | NOK 50.00 +37.4% | 10.0% | NOK 55.00 | NOK 45.00 | NOK 32.40 | 2 |
Apr ’24 | NOK 40.10 | NOK 50.00 +24.7% | 10.0% | NOK 55.00 | NOK 45.00 | NOK 35.60 | 2 |
Mar ’24 | NOK 36.50 | NOK 50.00 +37.0% | 10.0% | NOK 55.00 | NOK 45.00 | NOK 37.00 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.